Pirtobrutinib for Leukemia
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies how well pirtobrutinib works in treating elderly patients with chronic lymphocytic leukemia (CLL). Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib work by blocking the action of the BTK protein that signals cancer cells to multiply. These are very effective, tolerable, and commonly used to treat people with CLL, but they may lead to drug resistance over time. Pirtobrutinib, also a BTK inhibitor, may work better in treating elderly patients with CLL.
Who Is on the Research Team?
Jennifer A Woyach, MD
Principal Investigator
Ohio State University Comprehensive Cancer Center
Are You a Good Fit for This Trial?
This trial is for older adults diagnosed with chronic lymphocytic leukemia (CLL). Participants should be considered elderly and able to undergo study procedures. People with other types of leukemia or serious health issues that could interfere with the trial may not be eligible.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Pirtobrutinib
Trial Overview
The study is testing pirtobrutinib, a new BTK inhibitor pill, in elderly patients with CLL to see how well it works. The trial includes regular checkups, blood tests, bone marrow samples, scans, and questionnaires to monitor progress.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Patients receive pirtobrutinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, blood sample collection, and bone marrow biopsy and aspiration throughout the study.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jennifer Woyach
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.